IntelGenx (TSX:IGX; OTCQB:IGXT) announced that patient dosing has resumed in the ongoing Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) under a previously amended protocol using higher doses of Montelukast VersaFilm.
“Resumption of patient dosing after a COVID-related interruption of the study of more than one year is a significant milestone for this novel drug repurposing program, and we look forward to the BUENA trial producing valuable data that will provide more complete insight into the safety, feasibility, tolerability and efficacy of Montelukast VersaFilmin patients with mild-to-moderate AD,” Dr. Horst Zerbe, CEO of IntelGenx, said in a statement.
Dr. Ludwig Aigner, a member of IntelGenx’s SAB, said a significant unmet medical need remains for safe and effective treatments for mild-to-moderate AD. “We believe that Montelukast VersaFilm has the potential to be disease-modifying, and we are excited to have resumed patient dosing in this proof-of-concept trial.”
